OFIX - Orthofix Medical Inc Stock Price, Fair Value and News

15.08USD-0.03 (-0.20%)Delayed as of 17 May 2024, 11:04 am ET

Market Summary

USD15.08-0.03

Delayedas of 17 May 2024, 11:04 am

-0.20%

OFIX Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

OFIX Stock Price

View Fullscreen

OFIX RSI Chart

OFIX Valuation

Market Cap

567.1M

Price/Earnings (Trailing)

-4.48

Price/Sales (Trailing)

0.76

EV/EBITDA

-8.17

Price/Free Cashflow

-6.32

OFIX Price/Sales (Trailing)

OFIX Profitability

EBT Margin

-16.53%

Return on Equity

-22.18%

Return on Assets

-13.96%

Free Cashflow Yield

-15.81%

OFIX Fundamentals

OFIX Revenue

Revenue (TTM)

747.3M

Rev. Growth (Yr)

0.36%

Rev. Growth (Qtr)

-12.27%

OFIX Earnings

Earnings (TTM)

-126.5M

Earnings Growth (Yr)

40.89%

Earnings Growth (Qtr)

-62.44%

Breaking Down OFIX Revenue

52 Week Range

11.4821.60

(Low)(High)

Last 7 days

4.2%

Last 30 days

14.6%

Last 90 days

9.5%

Trailing 12 Months

-19.8%

How does OFIX drawdown profile look like?

OFIX Financial Health

Current Ratio

2.65

Debt/Equity

0.2

Debt/Cashflow

-0.26

OFIX Investor Care

Shares Dilution (1Y)

2.70%

Diluted EPS (TTM)

-3.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	747.3M	0	0	0
2023	529.5M	598.4M	668.5M	746.6M
2022	465.3M	462.0M	463.5M	460.7M
2021	407.3M	455.6M	457.0M	464.5M
2020	455.7M	413.0M	410.4M	406.6M
2019	453.4M	457.7M	459.5M	460.0M
2018	439.8M	442.4M	448.9M	453.0M
2017	413.8M	418.7M	425.5M	433.8M
2016	405.4M	408.5M	405.9M	409.8M
2015	392.0M	392.0M	392.2M	396.5M
2014	395.3M	398.7M	407.9M	402.3M
2013	435.3M	421.3M	407.3M	397.6M
2012	464.2M	459.2M	447.7M	440.2M
2011	538.6M	512.4M	490.8M	470.1M
2010	550.3M	555.0M	559.7M	564.4M
2009	0	0	0	545.6M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Orthofix Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	cedron jorge andres	acquired	375,002	13.09	28,648	clo
Apr 11, 2024	elting kimberley a.	sold (taxes)	-40,985	13.95	-2,938	president, global orthopedics
Apr 08, 2024	burzik catherine m	sold (taxes)	-675,726	14.23	-47,486	-
Apr 01, 2024	gillespie geoffrey c	sold (taxes)	-984	14.06	-70.00	cao
Apr 01, 2024	elting kimberley a.	sold (taxes)	-28,555	14.06	-2,031	president, global orthopedics
Mar 15, 2024	gillespie geoffrey c	acquired	49,999	13.74	3,639	cao
Feb 01, 2024	elting kimberley a.	sold (taxes)	-28,754	14.27	-2,015	president, global orthopedics
Jan 31, 2024	kummeth charles r.	acquired	115,982	13.89	8,350	-
Jan 31, 2024	finegan michael	acquired	115,982	13.89	8,350	-
Jan 31, 2024	bazaar alan lee	acquired	124,121	13.89	8,936	-

Which funds bought or sold OFIX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	AMUNDI	added	1,417	442,026	477,261	-%
May 15, 2024	MIRABELLA FINANCIAL SERVICES LLP	sold off	-100	-269,040	-	-%
May 15, 2024	Voya Investment Management LLC	reduced	-10.51	-104,002	2,781,360	-%
May 15, 2024	Cubist Systematic Strategies, LLC	reduced	-42.6	-1,159,430	1,878,150	0.01%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	44.56	1,033,240	2,887,960	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	sold off	-100	-313,908	-	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	added	4.98	141,538	1,223,300	0.09%
May 15, 2024	GLENVIEW CAPITAL MANAGEMENT, LLC	added	76.62	6,082,980	12,823,000	0.22%
May 15, 2024	ALGERT GLOBAL LLC	reduced	-13.61	-234,000	3,133,000	0.12%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-14.63	-551,275	6,298,020	-%

Are Funds Buying or Selling OFIX?

Are funds buying OFIX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OFIX

No. of Funds

Unveiling Orthofix Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 22, 2024	engine capital, l.p.	6.9%	2,565,743	SC 13D/A
Feb 14, 2024	armistice capital, llc	9.79%	3,600,000	SC 13G
Feb 13, 2024	vanguard group inc	5.44%	1,999,666	SC 13G/A
Feb 12, 2024	rubric capital management lp	9.97%	3,665,000	SC 13G
Feb 09, 2024	morgan stanley	5.6%	2,057,081	SC 13G
Feb 09, 2024	segall bryant & hamill, llc	0.1%	44,484	SC 13G/A
Jan 08, 2024	blackrock inc.	9.0%	3,317,319	SC 13G/A
Dec 13, 2023	engine capital, l.p.	6.7%	2,479,157	SC 13D/A
Nov 03, 2023	engine capital, l.p.	6.0%	2,196,178	SC 13D
Oct 30, 2023	first light asset management, llc	0.0%	0	SC 13G/A

Recent SEC filings of Orthofix Medical Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 22, 2024	8-K	Current Report
Apr 22, 2024	SC 13D/A	13D - Major Acquisition
Apr 17, 2024	3	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 16, 2024	S-8	Employee Benefits Plan
Apr 12, 2024	4	Insider Trading

Peers (Alternatives to Orthofix Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.4B	40.3B	-3.99%	-3.65%	32.43	4.52	-2.84%	-3.08%
BDX	68.4B	19.7B	2.45%	-5.81%	51.31	3.47	4.82%	-17.56%
ALGN	20.6B	3.9B	-10.40%	-6.17%	44.52	5.25	5.72%	46.72%
BAX	17.9B	14.9B	-11.17%	-17.84%	6.76	1.2	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.44%	23.99%	31.25	2.76	6.16%	35.06%
HSIC	9.5B	12.5B	4.37%	-2.87%	24.53	0.76	-0.61%	-18.83%
BIO	8.4B	2.6B	0.92%	-22.34%	-26.13	3.23	-6.25%	-68.62%
XRAY	5.9B	3.9B	-7.86%	-29.32%	-63	1.5	0.23%	91.03%
AXNX	3.5B	387.1M	0.46%	29.28%	-216.68	8.92	30.82%	65.57%
PDCO	2.3B	6.6B	0.82%	-4.37%	11.97	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	2.50%	-12.21%	-1.88	0.4	7.94%	-1661.78%
ANIK	378.1M	169.3M	-	-1.96%	-4.92	2.23	7.49%	-244.90%
ANGO	257.2M	324.0M	-1.38%	-32.77%	-1.34	0.79	-3.19%	-337.41%
APYX	53.0M	50.5M	10.79%	-74.07%	-2.32	1.05	14.25%	-10.06%
AEMD	1.0M	3.7M	-72.22%	29.03%	-0.09	0.28	5.77%	8.23%

Orthofix Medical Inc News

Latest updates

Orthofix Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-12.3%	175,831,000	200,415,000	184,006,000	187,016,000	175,204,000	122,229,000	113,996,000	118,070,000	106,418,000	125,064,000	112,428,000	121,394,000	105,593,000	117,619,000	110,985,000	73,135,000	104,823,000	121,494,000	113,499,000	115,850,000	109,112,000
Gross Profit	-6.9%	127,242,000	136,630,000	119,763,000	119,551,000	110,329,000	89,176,000	83,423,000	86,470,000	78,100,000	91,810,000	84,121,000	93,955,000	79,679,000	88,548,000	84,742,000	49,969,000	81,414,000	95,303,000	88,603,000	90,038,000	85,404,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	91,208,000	107,485,000	89,587,000	89,852,000
S&GA Expenses	2.3%	100,043,000	97,749,000	94,947,000	99,249,000	93,791,000	59,324,000	55,461,000	59,888,000	54,137,000	57,098,000	56,097,000	57,338,000	50,785,000	53,716,000	52,926,000	43,479,000	54,313,000	58,313,000	54,805,000	56,864,000	53,694,000
R&D Expenses	2.9%	19,492,000	18,941,000	18,559,000	19,424,000	23,307,000	13,152,000	11,943,000	12,758,000	11,212,000	13,243,000	12,360,000	13,121,000	10,897,000	10,365,000	9,962,000	8,765,000	9,964,000	8,446,000	7,982,000	8,980,000	9,229,000
EBITDA Margin	23.2%	-0.11	-0.14	-0.14	-0.13	-0.08	0.02	0.02	0.03	0.03	0.03	0.07	0.09	-	-	-	-	-	-	-	-	-
Interest Expenses	-1.3%	-4,558,000	-4,500,000	-1,576,000	-1,266,000	-1,289,000	-229,000	-277,000	-407,000	-375,000	-437,000	-433,000	-550,000	-417,000	-428,000	-731,000	-901,000	-423,000	-508,000	186,000	457,000	-257,000
Income Taxes	580.8%	851,000	125,000	472,000	1,508,000	611,000	75,000	1,344,000	553,000	71,000	23,207,000	-364,000	2,248,000	-207,000	14,948,000	607,000	1,592,000	-20,032,000	-7,456,000	13,656,000	1,219,000	-6,006,000
Earnings Before Taxes	-59.5%	-35,169,000	-22,049,000	-28,385,000	-37,918,000	-60,327,000	-6,987,000	-9,372,000	3,042,000	-4,389,000	-9,605,000	-2,535,000	4,668,000	-6,023,000	5,570,000	5,261,000	-16,832,000	5,633,000	4,230,000	-26,842,000	672,000	-5,109,000
EBT Margin	17.0%	-0.17	-0.20	-0.20	-0.19	-0.14	-0.04	-0.04	-0.03	-0.03	-0.03	0.00	0.02	-	-	-	-	-	-	-	-	-
Net Income	-62.4%	-36,020,000	-22,174,000	-28,857,000	-39,426,000	-60,938,000	-7,062,000	-10,716,000	2,489,000	-4,460,000	-32,812,000	-2,171,000	2,420,000	-5,816,000	-9,378,000	4,654,000	-18,424,000	25,665,000	11,686,000	-40,498,000	-547,000	897,000
Net Income Margin	16.5%	-0.17	-0.20	-0.20	-0.20	-0.14	-0.04	-0.10	-0.08	-0.08	-0.08	-0.03	-0.02	-	-	-	-	-	-	-	-	-
Free Cashflow	-37.1%	-29,138,000	-21,255,000	-21,395,000	-17,867,000	-45,492,000	-2,857,000	-6,391,000	-10,616,000	-13,038,000	5,554,000	3,907,000	-6,847,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.1%	906	925	906	901	917	459	450	462	462	477	500	502	514	526	517	596	493	496	476	489	479
Current Assets	-5.1%	399	420	394	399	410	256	247	255	255	270	260	258	263	270	255	344	240	261	238	233	224
Cash Equivalents	-18.6%	27.00	33.00	34.00	38.00	50.00	51.00	52.00	60.00	72.00	88.00	83.00	80.00	95.00	96.00	80.00	173	58.00	70.00	57.00	52.00	47.00
Inventory	-1.4%	219	222	222	222	222	100	100	97.00	89.00	83.00	85.00	82.00	84.00	85.00	83.00	82.00	83.00	82.00	81.00	79.00	79.00
Net PPE	-0.6%	158	159	153	141	137	58.00	58.00	59.00	59.00	59.00	59.00	62.00	62.00	64.00	64.00	65.00	65.00	63.00	63.00	64.00	64.00
Goodwill	0%	195	195	195	192	203	71.00	71.00	71.00	71.00	71.00	83.00	84.00	84.00	84.00	84.00	83.00	11.00	71.00	71.00	71.00	71.00
Liabilities	2.8%	336	327	290	261	253	122	116	120	126	140	136	140	159	169	162	251	138	168	169	141	136
Current Liabilities	-8.8%	151	165	153	142	138	84.00	78.00	81.00	88.00	106	80.00	82.00	99.00	104	93.00	90.00	66.00	85.00	89.00	68.00	64.00
Long Term Debt	23.6%	115	93.00	70.00	51.00	45.00	-	-	-	-	-	-	-	-	-	-	100	-	-	-	-	-
LT Debt, Current	150.0%	3.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	93.00	70.00	51.00	45.00	-	-	-	-	-	-	-	-	-	-	100	-	-	-	-	-
Shareholder's Equity	-4.7%	570	599	615	640	664	337	334	342	336	337	365	362	355	357	355	345	355	328	306	348	344
Retained Earnings	-24.0%	-186	-150	-127	-99.11	-59.69	1.00	8.00	19.00	17.00	21.00	54.00	56.00	54.00	59.00	69.00	64.00	83.00	58.00	46.00	87.00	87.00
Additional Paid-In Capital	0.9%	753	746	742	736	721	335	328	324	318	314	308	303	298	292	285	282	276	271	263	258	253
Shares Outstanding	0.7%	37.00	37.00	37.00	37.00	36.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	663	-	-	-	471	-	-	-	789	-	-	-	615	-	-	-	996	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-177.8%	-18,595	-6,694	477	-5,516	-34,020	2,348	-1,264	-4,913	-7,709	11,779	6,432	-2,177	2,441	22,291	21,887	17,630	12,464	11,943	11,746	9,383	-1,039
Share Based Compensation	177.9%	8,800	3,167	6,274	13,246	13,020	4,922	4,729	4,460	4,332	3,962	3,842	3,907	3,721	3,808	3,841	4,699	3,859	4,162	5,844	5,849	5,685
Cashflow From Investing	27.8%	-10,867	-15,053	-22,343	-12,819	17,084	-5,900	-5,473	-7,494	-5,667	-8,982	-4,239	-5,011	-4,781	-9,390	-14,372	-4,388	-24,184	-1,643	-4,543	-5,422	-11,316
Cashflow From Financing	-15.1%	21,453	25,280	18,251	5,808	15,983	1,498	-252	909	-2,233	2,052	855	-7,638	1,110	2,662	-101,335	101,603	315	1,922	-1,029	-1,185	-10,396

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OFIX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net sales	$ 188,608	$ 175,204
Cost of sales	61,366	64,875
Gross profit	127,242	110,329
Sales and marketing	100,043	93,791
General and administrative	31,648	48,811
Research and development	19,492	23,307
Acquisition-related amortization and remeasurement (Note 12)	5,396	4,134
Operating loss	(29,337)	(59,714)
Interest expense, net	(4,558)	(1,289)
Other income (expense), net	(1,274)	676
Loss before income taxes	(35,169)	(60,327)
Income tax expense	(851)	(611)
Net loss	$ (36,020)	$ (60,938)
Net loss per common share:
Basic	$ (0.95)	$ (1.71)
Diluted	$ (0.95)	$ (1.71)
Weighted average number of common shares:
Basic	37,741	35,734
Diluted	37,741	35,734
Other comprehensive loss, before tax
Unrealized [gain (loss)] on debt securities	$ 1,671	$ (63)
Currency translation adjustment	(1,038)	493
Other comprehensive income, before tax	633	430
Other comprehensive income, net of tax	633	430
Comprehensive loss	$ (35,387)	$ (60,508)

OFIX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 26,964	$ 33,107
Restricted cash	2,500	4,650
Accounts receivable, net of allowances of $8,398 and $7,130, respectively	125,617	128,098
Inventories	219,076	222,166
Prepaid expenses and other current assets	24,821	32,422
Total current assets	398,978	420,443
Property, plant, and equipment, net	158,132	159,060
Intangible assets, net	112,761	117,490
Goodwill	194,934	194,934
Other long-term assets	41,245	33,388
Total assets	906,050	925,315
Current liabilities
Accounts payable	57,147	58,357
Current portion of long-term debt	3,125	1,250
Current portion of finance lease liability	724	708
Other current liabilities	89,625	104,908
Total current liabilities	150,621	165,223
Long-term debt	115,071	93,107
Long-term portion of finance lease liability	18,345	18,532
Other long-term liabilities	51,698	49,723
Total liabilities	335,735	326,585
Contingencies (Note 8)
Shareholders’ equity
Common shares $0.10 par value; 100,000 shares authorized; 37,410 and 37,165 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	3,741	3,717
Additional paid-in capital	753,398	746,450
Accumulated deficit	(186,164)	(150,144)
Accumulated other comprehensive loss	(660)	(1,293)
Total shareholders’ equity	570,315	598,730
Total liabilities and shareholders’ equity	$ 906,050	$ 925,315

About Orthofix Medical Inc

Orthofix Medical Inc. operates spine and orthopedics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through Global Spine and Global Orthopedics segments. The Global Spine segment comprises the bone growth therapies products, which manufactures and distributes bone growth stimulator devices for enhance of bone fusion including adjunctive and noninvasive treatment of cervical and lumbar spine as well as a therapeutic treatment for non-spine; the spinal implants products designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and the biological products, such as regenerative products and tissue forms which allow physicians to treat a variety of spinal and orthopedic conditions. Global Orthopedics segment offers products and solutions that allow physicians to treat a variety of orthopedic conditions unrelated to the spine, which design, develop, and market the orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. It sells its products through distributors, sales representatives, hospitals, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.

CEO	Mr. Keith C. Valentine
WEBSITE	orthofix.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	1092

Orthofix Medical Inc Frequently Asked Questions

What is the ticker symbol for Orthofix Medical Inc? What does OFIX stand for in stocks?

OFIX is the stock ticker symbol of Orthofix Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Orthofix Medical Inc (OFIX)?

As of Thu May 16 2024, market cap of Orthofix Medical Inc is 567.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OFIX stock?

You can check OFIX's fair value in chart for subscribers.

What is the fair value of OFIX stock?

You can check OFIX's fair value in chart for subscribers. The fair value of Orthofix Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Orthofix Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OFIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Orthofix Medical Inc a good stock to buy?

The fair value guage provides a quick view whether OFIX is over valued or under valued. Whether Orthofix Medical Inc is cheap or expensive depends on the assumptions which impact Orthofix Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OFIX.

What is Orthofix Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, OFIX's PE ratio (Price to Earnings) is -4.48 and Price to Sales (PS) ratio is 0.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OFIX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Orthofix Medical Inc's stock?

In the past 10 years, Orthofix Medical Inc has provided -0.071 (multiply by 100 for percentage) rate of return.